Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
184M
-
Number of holders
-
142
-
Total 13F shares, excl. options
-
98.6M
-
Shares change
-
-9.17M
-
Total reported value, excl. options
-
$114M
-
Value change
-
-$11.7M
-
Put/Call ratio
-
3.08
-
Number of buys
-
58
-
Number of sells
-
-76
-
Price
-
$1.16
Significant Holders of HERON THERAPEUTICS, INC. /DE/ - Common Stock (HRTX) as of Q2 2023
175 filings reported holding HRTX - HERON THERAPEUTICS, INC. /DE/ - Common Stock as of Q2 2023.
HERON THERAPEUTICS, INC. /DE/ - Common Stock (HRTX) has 142 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 98.6M shares
of 184M outstanding shares and own 53.75% of the company stock.
Largest 10 shareholders include Rubric Capital Management LP (11.8M shares), BlackRock Inc. (8.38M shares), VANGUARD GROUP INC (8.14M shares), BAKER BROS. ADVISORS LP (8.13M shares), FRANKLIN RESOURCES INC (7.46M shares), JPMORGAN CHASE & CO (6.86M shares), GREAT POINT PARTNERS LLC (4.74M shares), Velan Capital Investment Management LP (4.5M shares), PALISADE CAPITAL MANAGEMENT, LP (4.14M shares), and Clearline Capital LP (2.67M shares).
This table shows the top 142 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.